Phase 1 and Phase 2 Studies of Salmonella Enterica Serovar Paratyphi A O-specific Polysaccharide-tetanus Toxoid Conjugates in Adults, Teenagers, and 2- to 4-year-old Children in Vietnam
Overview
Authors
Affiliations
Salmonella enterica serovar Paratyphi A O-specific polysaccharide (O-SP) was activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) and bound to tetanus toxoid (TT) with adipic acid dihydrazide as a linker (SPA-TT(1)) or directly (SPA-TT(2)). In mice, these two conjugates elicited high levels of immunoglobulin G (IgG) anti-lipopolysaccharide (LPS) in serum with bactericidal activity (E. Konadu, J. Shiloach, D. A. Bryla, J. B. Robbins, and S. C. Szu, Infect. Immun. 64:2709-2715, 1996). The safety and immunogenicity of the two conjugates were then evaluated sequentially in Vietnamese adults, teenagers, and 2- to 4-year-old children. None of the vaccinees experienced significant side effects, and all had preexisting LPS antibodies. At 4 weeks after injection, there were significant increases of the geometric mean IgG and IgM anti-LPS levels in the adults and teenagers: both conjugates elicited a greater than fourfold rise in the IgG anti-LPS level in serum in >/=80% of the volunteers. SPA-TT(2) elicited slightly higher, though not statistically significantly, levels of IgG anti-LPS than did SPA-TT(1) in these age groups. Accordingly, only SPA-TT(2) was evaluated in the 2- to 4-year-old children. On a random basis, one or two injections were administered 6 weeks apart to the children. No significant side effects were observed, and the levels of preexisting anti-LPS in serum were similar in children of all ages. A significant rise in the IgG anti-LPS titer was elicited by the first injection (P = 0.0001); a second injection did not elicit a booster response. Representative sera from all groups had bactericidal activity that could be adsorbed by S. enterica serovar Paratyphi A LPS.
Typhoid & paratyphoid vaccine development in the laboratory: a review & in-country experience.
Chakraborty S, Das S Indian J Med Res. 2024; 160(3&4):379-390.
PMID: 39632634 PMC: 11619049. DOI: 10.25259/IJMR_1382_2024.
Design of a Glycoconjugate Vaccine Against Paratyphi A.
Alfini R, Carducci M, Massai L, De Simone D, Mariti M, Rossi O Vaccines (Basel). 2024; 12(11).
PMID: 39591175 PMC: 11599127. DOI: 10.3390/vaccines12111272.
Carducci M, Massai L, Lari E, Semplici B, Grappi S, Maria N Front Immunol. 2024; 15:1443137.
PMID: 39539546 PMC: 11557361. DOI: 10.3389/fimmu.2024.1443137.
Haldar R, Dhar A, Ganguli D, Chakraborty S, Pal A, Banik G Front Immunol. 2024; 14:1304170.
PMID: 38264668 PMC: 10804610. DOI: 10.3389/fimmu.2023.1304170.
Combination Vaccines: Moving Beyond Typhoid.
MacLennan C, Stanaway J, Grow S, Vannice K, Steele A Open Forum Infect Dis. 2023; 10(Suppl 1):S58-S66.
PMID: 37274529 PMC: 10236507. DOI: 10.1093/ofid/ofad041.